171 related articles for article (PubMed ID: 8750585)
1. Abnormal expression of MDM-2 in breast carcinomas.
Bueso-Ramos CE; Manshouri T; Haidar MA; Yang Y; McCown P; Ordonez N; Glassman A; Sneige N; Albitar M
Breast Cancer Res Treat; 1996; 37(2):179-88. PubMed ID: 8750585
[TBL] [Abstract][Full Text] [Related]
2. Molecular abnormalities of mdm-2 in human sarcomas.
Buesoramos C; Yang Y; Manshouri T; Feltz L; Ayala A; Glassman A; Albitar M
Int J Oncol; 1995 Nov; 7(5):1043-8. PubMed ID: 21552929
[TBL] [Abstract][Full Text] [Related]
3. A molecular and immunohistochemical study of the MDM2 protein isoforms and p53 gene product in bronchogenic carcinoma.
Gorgoulis VG; Zoumpourlis V; Rassidakis GZ; Karameris A; Rassidakis AN; Spandidos DA; Kittas C
J Pathol; 1996 Oct; 180(2):129-37. PubMed ID: 8976869
[TBL] [Abstract][Full Text] [Related]
4. MDM-2 oncoprotein overexpression in laryngeal squamous cell carcinoma: association with wild-type p53 accumulation.
Pruneri G; Pignataro L; Carboni N; Luminari S; Capaccio P; Neri A; Buffa R
Mod Pathol; 1997 Aug; 10(8):785-92. PubMed ID: 9267820
[TBL] [Abstract][Full Text] [Related]
5. Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes.
Olson DC; Marechal V; Momand J; Chen J; Romocki C; Levine AJ
Oncogene; 1993 Sep; 8(9):2353-60. PubMed ID: 7689721
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical and molecular evaluation of the mdm-2 gene product in bronchogenic carcinoma.
Gorgoulis VG; Rassidakis GZ; Karameris AM; Papastamatiou H; Trigidou R; Veslemes M; Rassidakis AN; Kittas C
Mod Pathol; 1996 May; 9(5):544-54. PubMed ID: 8733770
[TBL] [Abstract][Full Text] [Related]
7. Expression of mdm-2 and p53 protein in transitional cell carcinoma.
Barbareschi M; Girlando S; Fellin G; Graffer U; Luciani L; Dalla Palma P
Urol Res; 1995; 22(6):349-52. PubMed ID: 7537927
[TBL] [Abstract][Full Text] [Related]
8. Expression profile of MDM-2 proteins in chronic lymphocytic leukemia and their clinical relevance.
Haidar MA; El-Hajj H; Bueso-Ramos CE; Manshouri T; Glassman A; Keating MJ; Maher A
Am J Hematol; 1997 Mar; 54(3):189-95. PubMed ID: 9067496
[TBL] [Abstract][Full Text] [Related]
9. Clinical relevance of immunohistochemical expression of p53-targeted gene products mdm-2, p21 and bcl-2 in breast carcinoma.
Bánkfalvi A; Tory K; Kemper M; Breukelmann D; Cubick C; Poremba C; Füzesi L; Lellè RJ; Böcker W
Pathol Res Pract; 2000; 196(7):489-501. PubMed ID: 10926327
[TBL] [Abstract][Full Text] [Related]
10. Elevated levels of MDM-2 and p53 expression are associated with high grade non-Hodgkin's lymphomas.
Finnegan MC; Goepel JR; Royds J; Hancock BW; Goyns MH
Cancer Lett; 1994 Nov; 86(2):215-21. PubMed ID: 7982210
[TBL] [Abstract][Full Text] [Related]
11. p53 protein expression but not mdm-2 protein expression is associated with rapid tumor cell proliferation and prognosis in renal cell carcinoma.
Moch H; Sauter G; Gasser TC; Buchholz N; Bubendorf L; Richter J; Jiang F; Dellas A; Mihatsch MJ
Urol Res; 1997; 25 Suppl 1():S25-30. PubMed ID: 9079753
[TBL] [Abstract][Full Text] [Related]
12. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
[TBL] [Abstract][Full Text] [Related]
13. Mdm2 overexpression and p14(ARF) inactivation are two mutually exclusive events in primary human lung tumors.
Eymin B; Gazzeri S; Brambilla C; Brambilla E
Oncogene; 2002 Apr; 21(17):2750-61. PubMed ID: 11965548
[TBL] [Abstract][Full Text] [Related]
14. mdm-2 oncogene expression in non-Hodgkin's lymphomas.
Kawamata N; Miller C; Levy V; Shintaku IP; Koeffler HP; Said JW
Diagn Mol Pathol; 1996 Mar; 5(1):33-8. PubMed ID: 8919543
[TBL] [Abstract][Full Text] [Related]
15. The human MDM-2 oncogene is overexpressed in leukemias.
Bueso-Ramos CE; Yang Y; deLeon E; McCown P; Stass SA; Albitar M
Blood; 1993 Nov; 82(9):2617-23. PubMed ID: 8219216
[TBL] [Abstract][Full Text] [Related]
16. p21/waf1/cip1 and mdm-2 expression in breast carcinoma patients as related to prognosis.
Jiang M; Shao ZM; Wu J; Lu JS; Yu LM; Yuan JD; Han QX; Shen ZZ; Fontana JA
Int J Cancer; 1997 Oct; 74(5):529-34. PubMed ID: 9355976
[TBL] [Abstract][Full Text] [Related]
17. Multiple patterns of MDM-2 deregulation in human leukemias: implications in leukemogenesis and prognosis.
Bueso-Ramos CE; Manshouri T; Haidar MA; Huh YO; Keating MJ; Albitar M
Leuk Lymphoma; 1995 Mar; 17(1-2):13-8. PubMed ID: 7773150
[TBL] [Abstract][Full Text] [Related]
18. Transition from in situ to invasive testicular germ cell neoplasia is associated with the loss of p21 and gain of mdm-2 expression.
Datta MW; Macri E; Signoretti S; Renshaw AA; Loda M
Mod Pathol; 2001 May; 14(5):437-42. PubMed ID: 11353054
[TBL] [Abstract][Full Text] [Related]
19. mdm-2 expression in human testicular germ-cell tumors and its clinical value.
Eid H; Institoris E; Géczi L; Bodrogi I; Bak M
Anticancer Res; 1999; 19(4C):3485-90. PubMed ID: 10629640
[TBL] [Abstract][Full Text] [Related]
20. mdm-2 expression correlates with wild-type p53 status in esophageal adenocarcinoma.
Soslow RA; Altorki NK; Yang G; Xie D; Yang CS
Mod Pathol; 1999 Jun; 12(6):580-6. PubMed ID: 10392633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
